Severe acute respiratory syndrome coronavirus 2 peptide antigens (SARS-CoV-2 peptide antigens)

SARS-CoV-2 peptide antigens are short amino acid sequences derived from the structural and non-structural proteins of the Severe Acute Respiratory Syndrome Coronavirus 2, including the Spike (S), Nucleocapsid (N), Membrane (M), and Envelope (E) proteins. These peptides represent specific epitopes that are recognized by the host's immune system to trigger a protective response. In therapeutic and prophylactic applications, they are primarily used in the development of peptide-based vaccines, which offer a safer and more stable alternative to traditional whole-virus or live-attenuated vaccines. By focusing the immune response on highly conserved or critical functional domains of the virus, these antigens aim to provide broad protection against multiple variants (Source: NIH, National Institute of Allergy and Infectious Diseases; PubMed, PMID: 32814528). Beyond vaccines, SARS-CoV-2 peptide antigens are essential components in diagnostic assays designed to measure cellular immunity, such as T-cell response monitoring. They interact with the immune system by binding to B-cell receptors or being presented via MHC molecules to T-cell receptors. While they are highly specific, a significant challenge in their clinical use is the requirement for adjuvants to enhance their relatively low inherent immunogenicity and the need to account for human leukocyte antigen (HLA) polymorphism in the global population. Their role is central to both the prevention of COVID-19 and the understanding of long-term immunity following infection or vaccination (Source: World Health Organization; Frontiers in Immunology, 2020).

Other names

SARS-CoV-2 epitopesCOVID-19 peptide antigensSARS-CoV-2 T-cell epitopesSARS-CoV-2 B-cell epitopesSARS-CoV-2 immunogenic peptides

SARS-CoV-2 peptide antigens function by mimicking specific fragments of viral proteins to stimulate the host's adaptive immune system. When administered as vaccines, these peptides are processed and presented by Major Histocompatibility Complex (MHC) class I and II molecules on antigen-presenting cells. This presentation triggers the activation of CD4+ helper T-cells and CD8+ cytotoxic T-cells, as well as the production of neutralizing antibodies by B-cells, establishing immunological memory against the virus (Source: PubMed, PMID: 33035203; Nature Communications, 2021).